Jade Biosciences, Inc. (JBIO): Form 8-K filed 2026-11-13

Accepted by EDGAR: 2026-11-13 07:20 ET
Event date: 2026-11-13
Accession no.: 0001193125-26-459287
Original filing: SEC EDGAR filing index

AI summary of the filing text. It can contain mistakes; the original filing is authoritative.

Jade Biosciences reports third quarter results and updates clinical trial plans

Jade Biosciences reported a third quarter net loss of $35.1 million and cash, cash equivalents, and investments of $475.7 million as of September 30, 2026. The company expects its existing funds to support operations into the fourth quarter of 2028. It expects to initiate the JADE101 Phase 3 EVERGREEN trial and a JADE301 Phase 1 trial in the fourth quarter of 2026.

Net loss was $35.1 million for the third quarter ended September 30, 2026, compared to $25.2 million for the third quarter of 2025.
Cash, cash equivalents, and investments totaled $475.7 million as of September 30, 2026.
Jade expects to initiate the JADE101 Phase 3 EVERGREEN trial in IgA nephropathy in the fourth quarter of 2026.
Jade expects to initiate a JADE301 Phase 1 trial in healthy volunteers in the fourth quarter of 2026.

earningsproductguidance

Items reported

Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed".
Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.

Documents

Type	Description	Document
8-K	8-K	d157312d8k.htm
EX-99.1	EX-99.1	d157312dex991.htm

The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.